TNGX

1.27

7.30% -0.10

Dopo l'orario di chiusura: 1.27

Tango Therapeutics Inc (TNGX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TNGX Giù? Forum Previsione

Precedente Chiudi:

$1.37

Aprire:

$1.28

Volume 24 ore:

681.40K

Relative Volume:

0.90

Capitalizzazione di mercato:

$137.30M

Reddito:

$42.51M

Utile/perdita netta:

$-116.49M

Rapporto P/E:

-1.1339

EPS:

-1.12

Flusso di cassa netto:

$-120.82M

1 W Prestazione:

-21.12%

1M Prestazione:

-33.16%

6M Prestazione:

-81.59%

1 anno Prestazione:

-83.46%

Intervallo 1D:

$1.23

$1.34

Intervallo di 1 settimana:

$1.23

$1.63

Portata 52W:

$1.23

$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Nome

Tango Therapeutics Inc

Settore

Healthcare (1174)

Industria

Biotechnology (678)

Telefono

(857) 320-4900

Indirizzo

201 BROOKLINE AVENUE, BOSTON

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

TNGX's Discussions on Twitter

Confronta TNGX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TNGX Tango Therapeutics Inc	1.27	137.30M	42.51M	-116.49M	-120.82M	-1.12
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-07-17	Iniziato	Jefferies	Buy
2024-04-04	Iniziato	Cantor Fitzgerald	Overweight
2024-02-12	Iniziato	Piper Sandler	Overweight
2023-12-08	Iniziato	B. Riley Securities	Buy
2022-10-20	Aggiornamento	H.C. Wainwright	Neutral → Buy
2021-09-20	Iniziato	SVB Leerink	Outperform

Mostra tutto

Tango Therapeutics Inc Borsa (TNGX) Ultime notizie

12:30 PM

TNGX’s Wild Ride: Down -55.66% – What’s Next for TNGX? - investchronicle.com

12:30 PM

Mar 31, 2025

Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 30, 2025

Mar 29, 2025

Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 29, 2025

Mar 25, 2025

Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire

Mar 25, 2025

Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan

Mar 25, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com

Mar 24, 2025

Mar 21, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World

Mar 21, 2025

Mar 13, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Mar 13, 2025

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

Mar 13, 2025

Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025

Mar 06, 2025

Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 06, 2025

Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025

Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025